Exosomal miR-19a and IBSP cooperate to induce osteolytic bone metastasis of estrogen receptor-positive breast cancer
Kerui Wu,Jiamei Feng,Feng Lyu,Fei Xing,Sambad Sharma,Yin Liu,Shih-Ying Wu,Dan Zhao,Abhishek Tyagi,Ravindra Pramod Deshpande,Xinhong Pei,Marco Gabril Ruiz,Hiroyuki Takahashi,Shunsuke Tsuzuki,Takahiro Kimura,Yin-yuan Mo,Yusuke Shiozawa,Ravi Singh,Kounosuke Watabe
DOI: https://doi.org/10.1038/s41467-021-25473-y
IF: 16.6
2021-08-31
Nature Communications
Abstract:Abstract Bone metastasis is an incurable complication of breast cancer. In advanced stages, patients with estrogen-positive tumors experience a significantly higher incidence of bone metastasis (>87%) compared to estrogen-negative patients (<56%). To understand the mechanism of this bone-tropism of ER + tumor, and to identify liquid biopsy biomarkers for patients with high risk of bone metastasis, the secreted extracellular vesicles and cytokines from bone-tropic breast cancer cells are examined in this study. Both exosomal miR-19a and Integrin-Binding Sialoprotein (IBSP) are found to be significantly upregulated and secreted from bone-tropic ER + breast cancer cells, increasing their levels in the circulation of patients. IBSP is found to attract osteoclast cells and create an osteoclast-enriched environment in the bone, assisting the delivery of exosomal miR-19a to osteoclast to induce osteoclastogenesis. Our findings reveal a mechanism by which ER + breast cancer cells create a microenvironment favorable for colonization in the bone. These two secreted factors can also serve as effective biomarkers for ER + breast cancer to predict their risks of bone metastasis. Furthermore, our screening of a natural compound library identifies chlorogenic acid as a potent inhibitor for IBSP-receptor binding to suppress bone metastasis of ER + tumor, suggesting its preventive use for bone recurrence in ER + patients.
multidisciplinary sciences